Journal
ONCOIMMUNOLOGY
Volume 5, Issue 12, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2016.1254856
Keywords
Daratumumab; durvalumab; ibrutinib; irradiation; multiple myeloma; nivolumab; PD-1; PD-L1; pembrolizumab; pidilizumab
Categories
Funding
- MH CZ - DRO - FNOs
- Ministry of Education, Youth and Sports (Specific university research of the Faculty of Medicine, University of Ostrava) [SGS10LF2016-17]
- Institutional Development Plan of University of Ostrava [IRP201550]
- Ministry of Health [15-29667A]
Ask authors/readers for more resources
The introduction of PD-1/PD-L1 pathway inhibitors has marked a significant milestone in the treatment of various types of solid tumors. The current situation in multiple myeloma ( MM) is rather unclear, as distinct research groups have reported discordant results. This discrepancy dominantly concerns the expression of PD-1/PD-L1 molecules as well as the identification of the responsible immune effector cell population. The results of monotherapy with PD-1/PD-L1 inhibitors have been unsatisfactory in MM, suggesting that a combination approach is needed. The most logical partners are immunomodulatory agents as they possess many synergistic effects. We are also proposing other rational and promising combinations (e.g., daratumumab, ibrutinib, anti-CD137) that warrant further investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available